The proteasome inhibitor bortezomib for instance decreases MM related inflammation amongst others through inhibition of NF-κB and interaction with inflammation cytokines such as tumor necrosis factor or interleukin-6. The gene discussed is TNF; the disease is Miyoshi myopathy.